Drug Trial Radar · NCT03482011
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
530
Actual
Start
Apr 24, 2018
Primary completion
Mar 21, 2019
Study completion Jan 16, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
MirikizumabDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Static Physician's Global Assessment of (sPGA) (0,1) With at Least a 2-point Improvement From BaselineTime frame: Week 16
- Percentage of Participants Achieving a ≥90% Improvement From Baseline in Psoriasis Area and Severity Score (PASI 90)Time frame: Week 16
Locations
69 sites in 9 countries. Site status is shown where the registry gives one.
Univ of Connecticut
Farmington, Connecticut
Florida Academic Dermatology Centers
Coral Gables, Florida
Renstar Medical Research
Ocala, Florida
Forward Clinical Trials, Inc
Tampa, Florida
Arlington Dermatology
Rolling Meadows, Illinois
The South Bend Clinic
South Bend, Indiana
Oregon Medical Research Center
Portland, Oregon
Dermatology and Skin Surgery Center
Exton, Pennsylvania
University of Utah MidValley Dematology
Murray, Utah
Multicare Health System
Tacoma, Washington
Charité Universitätsmedizin Berlin
Berlin, Germany
ISA GmbH
Berlin, Germany
Universitätsklinikum Hamburg - Eppendorf
Hamburg, Germany
Clinical Research Hamburg GmbH
Hamburg, Germany
Gemeinschaftspraxis Mahlow
Mahlow, Brandenburg, Germany
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany
Praxis Gerlach
Dresden, Saxony, Germany
Toho University School of Medicine, Sakura Hospital
Sakura, Chiba, Japan
Takagi Dermatological Clinic
Obihiro, Hokkaido, Japan
Kanto Rosai Hospital
Kawasaki, Kanagawa, Japan
Yokohama City University Hospital
Yokohama, Kanagawa, Japan
Ryukyu University Hospital
Nakagami-gun, Okinawa, Japan
Kume Clinic
Nishi-ku Sakai-shi, Osaka, Japan
Shimane University Hospital
Izumo, Shimane, Japan
Tokyo Medical University Hachioji Medical Center
Hachiōji, Tokyo, Japan
NTT Medical Center Tokyo
Shinagawa-KU, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Seibo Hospital
Shinjuku-ku, Tokyo, Japan
Shirasaki Clinic
Takaoka-shi, Toyama, Japan
RM Pharma Specialists S.A. de C.V.
Distrito Federal, Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C
Durango, Mexico
Centro Medico del Angel S.C.
Mexicali, Estado de Baja California, Mexico
Instituto Dermatologico de Jalisco Dr. Jose Barba Rubio
Zapopan, Jalisco, Mexico
Hospital de Jesus
Mexico City, Mexico City, Mexico
Clínica Enfermedades Crónicas y Procedimientos Especiales SC
Morella, Michoacán, Mexico
B&B Investigaciones Medicas, SC
Mazatlán, Sinaloa, Mexico
Kohler Milstein Research, S.A. de C.V.
Mérida, Yucatán, Mexico
NZOZ ZDROWIE Osteo-Medic
Bialystok, Poland
"Dermed" Centrum Medyczne Sp. z o.o.
Lodz, Poland
Lubelskie Centrum Diagnostyczne
Świdnik, Poland
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.